Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | TPI1 | P60174 | 2/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9939662 | 0.89 | TSHR (0.43) | LPAR2LPAR1ENPP2TPI1LPAR3 | |
| SCHEMBL23294899 | 0.82 | LPAR2 (0.49) | LPAR2LPAR1ENPP2TPI1LPAR3 | |
| SCHEMBL26755912 | 0.80 | LPAR1 (0.55) | LPAR2LPAR1ENPP2TPI1LPAR3 | |
| SCHEMBL23294900 | 0.80 | LPAR2 (0.48) | LPAR2LPAR1ENPP2TPI1LPAR3 | |
| SCHEMBL23294898 | 0.80 | LPAR2 (0.48) | LPAR2LPAR1ENPP2TPI1LPAR3 | |
| SCHEMBL31527704 | 0.80 | LPAR2 (0.48) | LPAR2LPAR1ENPP2TPI1LPAR3 | |
| SCHEMBL17753978 | 0.77 | LPAR1 (0.64) | LPAR2LPAR1ENPP2LPAR3TSHR | |
| SCHEMBL12473535 | 0.77 | LPAR1 (0.52) | LPAR2LPAR1ENPP2TPI1LPAR3 | |
| SCHEMBL17151457 | 0.77 | LPAR1 (0.46) | LPAR2LPAR1ENPP2TPI1LPAR3 | |
| SCHEMBL3239278 | 0.77 | LPAR2 (0.44) | LPAR2LPAR1ENPP2TPI1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630638-B2 | Methods and compositions for diabetes treatment and β-cell regeneration | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | claimed |
| US-20250074989-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC DISEASE | METANOIA BIO INC (US) | 2025-03-06 | — | — | US | claimed |
| US-20240269111-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC (US) | 2024-08-15 | — | — | US | claimed |
| US-20240269124-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC (US) | 2024-08-15 | — | — | US | claimed |
| US-20240262916-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE | METANOIA BIO INC (US) | 2024-08-08 | — | — | US | claimed |
| EP-4340836-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | claimed |
| EP-4340896-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | claimed |
| EP-4340835-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | claimed |
| EP-4340897-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC AND HEPATIC DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | claimed |
| WO-2022245697-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2022-11-24 | — | — | WO | claimed |
| WO-2022245702-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2022-11-24 | — | — | WO | claimed |
| WO-2022245698-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC AND HEPATIC DISEASE | METANOIA BIO INC. (US) | 2022-11-24 | — | — | WO | claimed |
| WO-2022245711-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC. (US) | 2022-11-24 | — | — | WO | claimed |
| US-20210379087-A1 | COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2021-12-09 | — | — | US | claimed |
| CN-113347969-A | Composition for eliminating senescent cells | 维也纳自然资源与生命科学大学 | 2021-09-03 | — | — | CN | claimed |
| US-20210130381-A1 | One-Step Synthesis of Phosphate-Based Inhibitors and Applications Thereof | NORTH CAROLINA STATE UNIVERSITY | 2021-05-06 | — | — | US | claimed |
| EP-3643305-A1 | COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS | Universität für Bodenkultur Wien (AT) | 2020-04-29 | — | — | EP | claimed |
| US-12630638-B2 | Methods and compositions for diabetes treatment and β-cell regeneration | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-5401880-A | Mercaptohydroxy diamides | OCULON CORPORATION (US) | 1995-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130381-A1 | One-Step Synthesis of Phosphate-Based Inhibitors and Applications Thereof | ALDOA, DERA, RPIA | LPAR2 1122/4885LPAR1 861/4885ENPP2 98/4885 |
| US-12630638-B2 | Methods and compositions for diabetes treatment and β-cell regeneration | IAPP, APP, SLC2A3 | LPAR2 3033/4885LPAR1 4173/4885ENPP2 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.